Nano‐Enabled Systemic Delivery of STING Agonist by Engineered Silicasome for Potent Antitumor Immunotherapy
Advanced Science · 2026-06 · 13 (34)
DOI: 10.1002/advs.202523722 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 09.04.2026. Verfasst von Wenjing Zhou und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Tianjin University, Tianjin, China. Hauptthemen laut MEDLINE: Immunotherapy, Membrane Proteins, Silicon Dioxide, Nanoparticles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Zhejiang Provincial Natural Science Foundation of China, Pioneer" and "Leading Goose" R&D Program of Zhejiang.
Abstract (Originalsprache)
Activation of the STING pathway represents a potent strategy for cancer immunotherapy. However, the instability and systemic toxicity of STING agonists, especially cyclic dinucleotides (CDNs), limit their use via local administration with poor efficacy against metastatic or inaccessible tumors. Here, we develop an engineered silicasome nanocarrier for systemic delivery of the CDN ADU‐S100 (ADU‐Sili). Comprising ADU‐S100‐loaded mesoporous silica nanoparticles (MSNPs) coated with lipid bilayer, ADU‐Sili markedly enhanced tumor accumulation and antitumor efficacy compared with free ADU‐S100 and conventional liposomes in vivo. The advantage of systemic delivery was further demonstrated in bilateral tumors: ADU‐Sili induced systemic antitumor immunity, suppressing both tumors, whereas free ADU‐S100 inhibited only injected tumors. Immune profiling revealed that ADU‐Sili promoted dendritic cell maturation in lymph nodes, expanded cytotoxic and memory CD8 + T cells in spleens, elevated intratumoral effector cytokines, and polarized tumor‐associated macrophages toward an M1 phenotype. Notably, combining ADU‐Sili with immune checkpoint blockade (ICB) synergistically enhanced antitumor efficacy as demonstrated in more clinically relevant orthotopic tumor models. In summary, silicasomes enable effective systemic CDN delivery, eliciting robust immune and antitumor responses and overcoming intratumoral delivery limitations in STING‐based cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Sciences, Tianjin University, Tianjin, China.
- Zhejiang Cancer Hospital, The Key Laboratory of Zhejiang Province for Basic and Clinical Application of Functional Nucleic Acids, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
- Fuyang Institute, Zhejiang Chinese Medical University, Hangzhou, China.
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
ORCID-Profile: Xiangsheng Liu
Förderung
- National Natural Science Foundation of China
- Zhejiang Provincial Natural Science Foundation of China
- Pioneer" and "Leading Goose" R&D Program of Zhejiang
Zitieren
APA
Zhou, W., Li, Y., Sun, X., Yang, H., Shi, X., Yao, L., Jiang, J., Wang, E., Wang, H., Wei, Y., & Liu, X. (2026). Nano‐Enabled Systemic Delivery of STING Agonist by Engineered Silicasome for Potent Antitumor Immunotherapy. Advanced Science, 13(34). https://doi.org/10.1002/advs.202523722
Vancouver
Zhou W, Li Y, Sun X, Yang H, Shi X, Yao L, et al. Nano‐Enabled Systemic Delivery of STING Agonist by Engineered Silicasome for Potent Antitumor Immunotherapy. Advanced Science. 2026;13(34). doi:10.1002/advs.202523722
BibTeX
@article{Zhou2026,
author = {Zhou, Wenjing and Li, Yuting and Sun, Xudong and Yang, Honghong and Shi, Xiayu and Yao, Lijia and Jiang, Jinhong and Wang, Erli and Wang, Haoyang and Wei, Yi and Liu, Xiangsheng},
title = {Nano‐Enabled Systemic Delivery of STING Agonist by Engineered Silicasome for Potent Antitumor Immunotherapy},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {34},
doi = {10.1002/advs.202523722}
}
EUVIMED